rhBMP-2 is safe and improves outcomes in open tibial fractures .
Questo studio è stato identificato come potenzialmente ad alto impatto.
La metrica High Impact di OE, guidata dall'AI, stima l'influenza che un articolo potrebbe avere integrando i segnali della rivista in cui è stato pubblicato e il contenuto scientifico dell'articolo stesso.
Sviluppato utilizzando un'elaborazione del linguaggio naturale all'avanguardia, il modello High Impact di OE prevede in modo più accurato la futura performance citazionale di uno studio rispetto al solo fattore di impatto della rivista.
Ciò consente di riconoscere prima le ricerche clinicamente significative e aiuta i lettori a concentrarsi sugli articoli che hanno maggiori probabilità di influenzare la pratica futura.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2014;2(9):25 J Bone Joint Surg Am. 2002 Dec;84-A(12):2123-34450 patients with an open tibial fracture were randomized to receive the standard of care with either intramedullary nail fixation and routine soft-tissue management (the control group), an implant containing 0.75 mg/mL of rhBMP-2 alongside the standard care, or an implant containing 1.50 mg/mL of rhBMP-2 alongside the standard care. The rhBMP-2 implant was placed over the fracture at the time of wound closure. At 12 months, the 1.50-mg/mL rhBMP-2 group had a 44% reduction in the risk of failure, significantly fewer invasive interventions and hardware failures, faster wound-healing and significantly faster fracture healing than the control patients. .
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Sì = 1
Incerto = 0,5
Non rilevante = 0
No = 0
La valutazione dei criteri di segnalazione valuta la trasparenza con cui gli autori riportano le caratteristiche metodologiche e sperimentali dello studio all'interno della pubblicazione. La valutazione è suddivisa in cinque categorie che vengono presentate di seguito.
4/4
Aleatorización
4/4
Medición de resultados
2/4
Inclusión / exclusión
4/4
Descripción de la terapia
4/4
Estadísticas
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
L'Indice di Fragilità è uno strumento che aiuta l'interpretazione dei risultati significativi, fornendo una misura della forza di un risultato. L'Indice di Fragilità rappresenta il numero di eventi consecutivi che devono essere aggiunti a un risultato dicotomico per rendere il risultato non più significativo. Un numero piccolo rappresenta un risultato più debole, mentre un numero grande rappresenta un risultato più forte.
Perché questo studio era necessario ora?
Open tibial fractures are associated with a high rate of complications, including delayed bone union and nonunion. Secondary interventions to promote union of open tibial fractures are associated with high rates of patient morbidity and reduced quality of life. Recombinant human bone morphogenetic protein-2 (rhBMP-2) has shown promise in animal and human studies as an osteoinductive agent and it is thought to have a positive role in improving union and reducing secondary interventions. This study was needed to assess the safety and efficacy of rhBMP-2 in the treatment of open tibial fractures.
Qual era la domanda di ricerca principale?
In patients with an open tibial fracture, what is the safety and efficacy of an rhBMP-2 implant based on dose and compared to standard of care alone over 12 months?
- The percentages of patients requiring secondary interventions for fracture healing were 26% and 37% in the higher and lower dose groups respectively, compared with 46% in the control group (p = 0.0004).
- The number and the invasiveness of these interventions were significantly lower in the higher dose group than in the control group (p=0.0326 for number and p=0.0264 for invasiveness).
- Among the higher dose group, there was a significant 44% reduction in the risk of secondary intervention compared with the control group (p=0.0005; relative risk=0.56; 95% confidence interval: 0.40-0.78).
- At 6 months, the healing rate observed in the higher dose group was 21% higher than that in the control group (p=0.0008). Kaplan-Meyer survival analysis indicated that the time to fracture healing was shorter in the higher dose group than in the control group (p=0.0022). This significance was not seen in the lower dose group.
- 32 patients (22%) in the control group had hardware failure compared with 16 patients (11%) in the higher dose group (p=0.0174).
- 83% of the patients in the higher dose group had soft-tissue healing 6 weeks after wound closure compared with 65% of the patients in the control group (p=0.0010).
Che cosa devo ricordare di più?
rhBMP-2 shows a significant and dose-dependent effect on improving the rate of fracture and wound healing, and reducing the risks of secondary intervention and hardware failure in open tibial fractures over 12 months.
Come influenzerà l'assistenza ai miei pazienti?
Patients may benefit from an implant of rhBMP-2 along with standard care for open tibial fractures to reduce the risk of complications over 12 months and improve the rate of healing. Additional studies may be needed with longer-term follow-up and assessment of functional criteria.
DISCLAIMER
Il contenuto di questa pagina è solo a scopo informativo e non intende sostituire la consulenza, la diagnosi o il trattamento medico professionale. Se ha bisogno di cure mediche, si rivolga sempre al suo medico o al pronto soccorso più vicino. Le opinioni, le convinzioni e i punti di vista espressi dalle persone sui contenuti presenti in questa pagina non riflettono le opinioni, le convinzioni e i punti di vista di OrthoEvidence.
0 di 4 articoli mensili GRATUITI sbloccati
